(68) illustrated that oral consumption of Lactobacillus-derived exopolysaccharide could bolster the efficacy of ICB therapy against CCL20-expressing tumors via inducing CCR6+ CD8+ T cells in Peyer’s patches and improving the TME in experimental mouse tumor models, which provided compelling evidence on the dietary ingestion of exopolysaccharide for further clinical trials. The gene discussed is CD8A; the disease is neoplasm.